DESCRIBE <http://purl.uniprot.org/SHA-384/5166B01A2D19F7E85267C91286C888CA1795A13A5E858C03784D59C90D5C18945E201733232A3369C84BEBA8658D0371>

Subject	Predicate	Object
http://purl.uniprot.org/SHA-384/5166B01A2D19F7E85267C91286C888CA1795A13A5E858C03784D59C90D5C18945E201733232A3369C84BEBA8658D0371	http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/5166B01A2D19F7E85267C91286C888CA1795A13A5E858C03784D59C90D5C18945E201733232A3369C84BEBA8658D0371	http://www.w3.org/2000/01/rdf-schema#comment	"We concluded that low serum gastrin is related to increased risk of ER(+) BC development. The results also established that CCKBR/ERK/P65 signaling function is generally tumor suppressive in ER(+) BC indicating therapies should focus on restoring not inhibiting CCKBR/ERK/P65 pathway activity."xsd:string
http://purl.uniprot.org/uniprot/#_12C606489C8D1392903914C7CDAA6366495DB90EE4DB6DB6F9AF03618A9AC9E5CBBB4A2629FA9F13A27F73E6CBED4CF0	http://www.w3.org/1999/02/22-rdf-syntax-ns#subject	http://purl.uniprot.org/SHA-384/5166B01A2D19F7E85267C91286C888CA1795A13A5E858C03784D59C90D5C18945E201733232A3369C84BEBA8658D0371
http://purl.uniprot.org/uniprot/A0A0E3VY36	http://purl.uniprot.org/core/mappedAnnotation	http://purl.uniprot.org/SHA-384/5166B01A2D19F7E85267C91286C888CA1795A13A5E858C03784D59C90D5C18945E201733232A3369C84BEBA8658D0371
http://purl.uniprot.org/uniprot/#_A0A0E3VY36-mappedCitation-30115027	http://purl.uniprot.org/core/mappedAnnotation	http://purl.uniprot.org/SHA-384/5166B01A2D19F7E85267C91286C888CA1795A13A5E858C03784D59C90D5C18945E201733232A3369C84BEBA8658D0371